-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
2021 is the first year of the "14th Five-Year Plan", which emphasizes "persistence in innovation-driven development"
.
In the field of biomedicine, in recent years, with the normalization of centralized procurement, simplified approval procedures, and accelerated medical insurance access, the pharmaceutical industry has accelerated its transformation and upgrading, and it has also entered the "hard technology" era
.
According to the prediction of CMH, the average growth rate of the health industry will reach 9.
5% in the first five years of the "14th Five-Year Plan", and the average growth rate in the next five years will drop to about 6.
5%, and the scale of the industry will reach 16.
3 trillion
.
So, where are the future development opportunities for the biomedical industry? The industry believes that there are 4 new development opportunities, namely, independent innovation, international cooperation, imitation (import) substitution, and cluster development
.
Among them, in terms of independent innovation, since the initiation of the self-purchasing policy, it has become more and more normalized, forcing competition among domestic pharmaceutical companies to transform from the past focus on marketing to innovation
.
With the implementation of a series of policies such as the simplification of the approval process for new drugs, the acceleration of medical insurance access, and the reform of the drug and medical device approval system, the independent innovation of domestic innovative medical devices will develop rapidly, and local enterprises with innovative R&D capabilities and advance layout are expected to obtain opportunities
.
In terms of international cooperation, with the implementation of some domestic policies such as international multi-clinical center clinical trials, local companies have become more frequent to go out and introduce in, and promote the innovation of domestic drug research and development to a higher level
.
Take PD-1 as an example.
In the past two years, many domestically-made PD1 products in China have entered into external authorization transactions with foreign-funded pharmaceutical companies, indicating that Chinese innovative drugs have been recognized by foreign-funded pharmaceutical companies
.
The industry pointed out that the background of PD-1 going overseas is that there are differences in the efficacy and indications of different PD1, which can meet the diverse needs of patients; the second is the rapid iteration of China's Me Better (catch-up) drug and high growth efficiency
.
It can meet the needs of patients at a more appropriate price and has a price advantage; third, PD1 as a backbone drug for tumor treatment has the prospect of combination drugs, which also brings opportunities for Chinese drug innovation
.
In terms of generic (import) substitution, with the implementation of policies such as the consistency evaluation of generic drugs and volume purchases, the original research drug is facing the competitive pressure of being replaced by generic drugs due to the successful bidding of generic drugs, and at the same time, local companies are forced to improve product quality.
, To be in line with international standards, to seize the market driven by quality, and to meet the needs of patients for treatment
.
At the same time, in recent years, policies to encourage the innovation and development of domestic medical devices have also been implemented.
The industry believes that it will help accelerate the localization of medical devices and realize the take-off of domestic medical devices
.
In addition, in terms of cluster development, benefiting from a variety of favorable factors such as national policies, markets, and capital, the industry believes that the development of national biomedical parks (bases, medicine valleys, science and technology cities, innovation demonstration zones) is in the ascendant
.
According to statistics, a batch of medical science parks, biological parks, and medicine valleys have been built in more than 80 regions (cities) in China
.
Among them, more mature industrial parks include Jilin Tonghua Pharmaceutical City, Shanghai Biomedical Technology Industrial Base, Zhongguancun Life Science Park, and Peking University Biological City
.
As many biomedical industrial parks have achieved fruitful results, the biomedical industry has become a new bright spot in the economic growth of domestic parks.
Driven by more favorable policies and measures, it is expected that the entire biomedical industry will still have a large room for development in the future
.
.
In the field of biomedicine, in recent years, with the normalization of centralized procurement, simplified approval procedures, and accelerated medical insurance access, the pharmaceutical industry has accelerated its transformation and upgrading, and it has also entered the "hard technology" era
.
According to the prediction of CMH, the average growth rate of the health industry will reach 9.
5% in the first five years of the "14th Five-Year Plan", and the average growth rate in the next five years will drop to about 6.
5%, and the scale of the industry will reach 16.
3 trillion
.
So, where are the future development opportunities for the biomedical industry? The industry believes that there are 4 new development opportunities, namely, independent innovation, international cooperation, imitation (import) substitution, and cluster development
.
Among them, in terms of independent innovation, since the initiation of the self-purchasing policy, it has become more and more normalized, forcing competition among domestic pharmaceutical companies to transform from the past focus on marketing to innovation
.
With the implementation of a series of policies such as the simplification of the approval process for new drugs, the acceleration of medical insurance access, and the reform of the drug and medical device approval system, the independent innovation of domestic innovative medical devices will develop rapidly, and local enterprises with innovative R&D capabilities and advance layout are expected to obtain opportunities
.
In terms of international cooperation, with the implementation of some domestic policies such as international multi-clinical center clinical trials, local companies have become more frequent to go out and introduce in, and promote the innovation of domestic drug research and development to a higher level
.
Take PD-1 as an example.
In the past two years, many domestically-made PD1 products in China have entered into external authorization transactions with foreign-funded pharmaceutical companies, indicating that Chinese innovative drugs have been recognized by foreign-funded pharmaceutical companies
.
The industry pointed out that the background of PD-1 going overseas is that there are differences in the efficacy and indications of different PD1, which can meet the diverse needs of patients; the second is the rapid iteration of China's Me Better (catch-up) drug and high growth efficiency
.
It can meet the needs of patients at a more appropriate price and has a price advantage; third, PD1 as a backbone drug for tumor treatment has the prospect of combination drugs, which also brings opportunities for Chinese drug innovation
.
In terms of generic (import) substitution, with the implementation of policies such as the consistency evaluation of generic drugs and volume purchases, the original research drug is facing the competitive pressure of being replaced by generic drugs due to the successful bidding of generic drugs, and at the same time, local companies are forced to improve product quality.
, To be in line with international standards, to seize the market driven by quality, and to meet the needs of patients for treatment
.
At the same time, in recent years, policies to encourage the innovation and development of domestic medical devices have also been implemented.
The industry believes that it will help accelerate the localization of medical devices and realize the take-off of domestic medical devices
.
In addition, in terms of cluster development, benefiting from a variety of favorable factors such as national policies, markets, and capital, the industry believes that the development of national biomedical parks (bases, medicine valleys, science and technology cities, innovation demonstration zones) is in the ascendant
.
According to statistics, a batch of medical science parks, biological parks, and medicine valleys have been built in more than 80 regions (cities) in China
.
Among them, more mature industrial parks include Jilin Tonghua Pharmaceutical City, Shanghai Biomedical Technology Industrial Base, Zhongguancun Life Science Park, and Peking University Biological City
.
As many biomedical industrial parks have achieved fruitful results, the biomedical industry has become a new bright spot in the economic growth of domestic parks.
Driven by more favorable policies and measures, it is expected that the entire biomedical industry will still have a large room for development in the future
.
